

Prognostic Significance of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score in Hepatocellular Carcinoma

Jing Zhou , Daofeng Yang

Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

Correspondence: Daofeng Yang, Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China, Tel +86-13387567780, Email yangdaofeng@aliyun.com

Purpose: HALP score consisting of hemoglobin content, albumin content, lymphocyte count, and platelet count can comprehensively evaluate the inflammatory response and nutritional status. Many researchers have indicated that the HALP score is an effective predictor of the overall prognosis of various tumors. However, there is no relevant research to suggest whether the HALP score can predict the prognosis of patients with hepatocellular carcinoma (HCC).

Patients and Methods: We retrospectively analyzed 273 HCC patients who underwent surgical resection. Hemoglobin content, albumin content, lymphocyte count, and platelet count in peripheral blood were measured for each patient. The relationship between the HALP score and overall survival (OS) was investigated.

Results: With a mean of 56.69 ± 1.25 months follow-up, the 1-, 3-, and 5-year OS was 98.9%, 76.9%, and 55.3% for all patients, respectively. HALP scores (HR=1.708, 95% CI=1.192–2.448, P=0.004) were significant independent risk factors of OS. The 1-, 3-, and 5-year OS were 99.3%, 84.3%, and 63.4% for patients with high HALP scores; and 98.6%, 69.8%, and 47.5% for patients with low HALP scores, respectively (P=0.018). In TNM I–II stage patients, compared with high HALP scores, low HALP scores have worse OS (P=0.039). In AFP positive patients, compared with high HALP scores, low HALP scores have worse OS (P=0.042).

Conclusion: Our research showed the preoperative HALP score is an independent predictive factor of overall prognosis, and a low HALP score indicates a worse prognosis in HCC patients who underwent surgical resection.

Keywords: hepatocellular carcinoma, survival, HALP score, surgical resection, prognostic marker

Introduction

HCC is the most common pathological type of primary liver cancer¹ and one of the most common cancers in the world.² Because of the high recurrence rate and high metastasis rate, its treatment and management are still a big challenge today. There are many ways to treat HCC.³ As we know, hepatectomy is one of the effective methods to treat HCC. Child-Pugh classification consisting of serum albumin, serum bilirubin, prothrombin time, ascites and hepatic encephalopathy is a practical tool to assess the prognosis of patients with liver cirrhosis.⁴ It is generally believed that the earlier the grading, the better the prognosis. Hepatectomy can be used as the first-line curative treatment for HCC patients with Child-Pugh A.⁵ Besides surgical resection, there are liver transplantation,⁶ local area therapy,⁷ targeted therapy^{8,9} and immunotherapy,¹⁰ etc. But the overall prognosis of HCC is not optimistic.

The inflammatory reaction and immune state of the body are both very important for the prognosis of the tumor. The tumor immune microenvironment is critical to the occurrence and development of liver cancer.¹¹ Many inflammatory markers based on hematology have been proven to be prognostic factors of HCC.^{12,13} As we all know, nutritional status plays a critical role in the occurrence, development, and prognosis of many diseases, and HCC is no exception.^{14–16} HALP score consisting of hemoglobin content, albumin content, lymphocyte count, and platelet count can comprehensively evaluate the inflammatory response and nutritional status. There is no relevant research to suggest whether the

HALP score can predict the overall survival of HCC patients who underwent hepatectomy. However, many researchers have shown that the HALP score is an effective predictive factor of the overall prognosis of various tumors,¹⁷ such as pancreatic cancer,¹⁸ gastrointestinal stromal tumor,¹⁹ esophageal cancer,²⁰ etc.

Non-invasive laboratory markers gamma-glutamyl transpeptidase-to-platelet ratio (GPR) and fibrosis-4 (Fib-4) are related to the level of liver fibrosis.^{21,22} They are also important indexes to evaluate the occurrence of HCC.^{23–26} In practical work, their acquisition methods are simple and easy for patients to accept. And they are considered to have important clinical significance. GPR is an effective factor to indicate the prognosis of liver cancer.^{27,28} Studies have suggested that Fib-4 is related to complications such as liver failure²⁹ and varicose veins³⁰ in liver cancer. Studies have shown that the level of Fib-4 can indicate the OS of patients with HCC,³¹ but others have shown that Fib-4 has no such effect.^{32,33}

Our main purpose is to explore the impact of the preoperative HALP score on the overall prognosis of HCC patients who underwent hepatectomy. And the predictive value of other important clinicopathological features and controversial markers in OS of patients with HCC was also evaluated.

Patients and Methods

Our study conformed to the provisions of the Declaration of Helsinki (as revised in 2013). We retrospectively analyzed HCC patients who underwent surgical resection in Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, from May 2016 to June 2017. All included patients met the following requirements: (1) primary liver cancer patients; (2) patients underwent surgical resection for the first time; (3) hepatocellular carcinoma was confirmed by postoperative pathological examination. Exclusion criteria: (1) combined with other malignant tumors; (2) anticancer treatment before operation; (3) under eighteen; (4) metastatic liver cancer; (5) recurrent liver cancer.

Clinical Variables

All the test results were taken from routine tests within 1 week before surgery. HALP score, GPR and Fib-4 were calculated using the following formulas, respectively: $\text{Fib} - 4 = [\text{age}(\text{year}) * \text{AST}(\text{U/L})] / [\text{platelet}(*10^9/\text{L}) * \sqrt{\text{ALT}(\text{U/L})}]$. $\text{GPR} = \gamma - \text{glutamyl transpeptidase}(\text{g/L}) / \text{platelet}(*10^9/\text{L})$.²⁸ $\text{HALP score} = \text{hemoglobin}(\text{g/L}) * \text{albumin}(\text{g/L}) * \text{Lymphocyte}(*10^9/\text{L}) / \text{platelet}(*10^9/\text{L})$.¹⁸

Follow-Up

The electronic medical record system was used to screen the inpatients in our hospital according to the above criteria. Telephone and electronic medical record systems were used for postoperative follow-up.

Statistical Analysis

Univariate analysis and multivariate analysis were performed using Cox regression analysis. Independent risk factors of OS were determined by multivariate analysis. In the univariate analysis, the variable that $P < 0.05$ was further included in the multivariate analysis. We used the Kaplan–Meier method to identify OS, and compared them with the Log rank test. Using the Kolmogorov–Smirnov test to evaluate the normality of the continuous variables. The mean \pm standard deviation expressed the continuous variables that conformed to the normal distribution and the median (interquartile range) expressed the continuous variables with a skewed distribution. The categorical variables have expressed the frequency and percentage. All statistical analyses were performed using MedCalc 20.0 and SPSS 25.0. P values < 0.05 were considered statistically significant.

Results

We enrolled 273 HCC patients who met the study conditions during the study period. There were 238 (87.2%) male and 35 (12.8%) female patients. The mean age was 53.99 ± 10.74 years (Table 1). With a mean of 56.69 ± 1.25 months follow-up, the 1-, 3-, and 5-year OS was 98.9%, 76.9%, and 55.3% for all patients, respectively (Figure 1).

Table 1 Clinical Features of All Patients

Features	N=273	Features	N=273
Gender (male/female)	238 (87.2%)/35 (12.8%)	Monocyte (*10 ⁹ /L)	0.46 (0.35–0.60)
Age	53.99 ± 10.74	Hemoglobin (g/L)	140.00 (127.50–151.50)
HBsAg ^a (+/-)	214 (78.4%)/59 (21.6%)	Platelet (*10 ⁹ /L)	164.00 (119.50–222.00)
Liver cirrhosis (yes/no)	139 (50.9%)/134 (49.1%)	ALT ^e (U/L)	25.00 (20.00–37.00)
Tumor number (1/≥2)	241 (88.3%)/32 (11.7%)	AST ^f (U/L)	27.00 (22.00–38.00)
Tumor diameter	4.70 (3.00–7.00)	Albumin (g/L)	41.251 ± 4.354
TNM ^b stage (I–II/III–IV)	212 (77.7%)/61 (22.3%)	TBil ^g (μmol/L)	13.00 (9.80–16.25)
Cell differentiation (poor/moderate/well)	122 (44.7%)/134 (49.1%)/17 (6.2%)	ALP ^h (U/L)	77.00 (60.50–101.00)
MVI ^c status (+/-)	71 (26.0%)/202 (74.0%)	γ-GT ⁱ (U/L)	49.00 (30.00–101.00)
WBC ^d (*10 ⁹ /L)	5.27 (4.31–6.77)	PT ^j (S)	13.80 (13.30–14.40)
Neutrophil (*10 ⁹ /L)	3.10 (2.39–4.14)	AFP ^k (ng/mL)	85.12 (5.50–1446.00)
Lymphocyte (*10 ⁹ /L)	1.48 (1.14–1.87)		

Notes: ^aHepatitis B surface antigen; ^bTumor node metastasis; ^cMicrovascular invasion; ^dWhite blood cell; ^eAlanine aminotransferase; ^fAspartate aminotransferase; ^gTotal bilirubin; ^hAlkaline phosphatase; ⁱγ-glutamyl transpeptidase; ^jProthrombin time; ^kAlpha-fetoprotein.

Optimal Cutoff Values of PT, GPR, Fib-4, ALT/AST, HALP Score, and AFP

The optimal cutoff values of PT, GPR, Fib-4, ALT/AST, and HALP scores were 14.35, 0.205, 2.824, 0.568, and 54.132, respectively (Figure 2). According to the definition of AFP level in our hospital, AFP >7.00 ng/mL is defined as AFP rising, that is, AFP positive; and AFP ≤7.00 ng/mL is defined as AFP normal, that is, AFP negative.

Association Between HALP Score and Clinical Characteristics

There were 134 patients with high HALP scores and 139 patients with low HALP scores. The chi-square test was used to verify the relationship between preoperative HALP score and clinical features. Low HALP scores were found to be related to the high TNM stage (P=0.001, Table 2).

Prognostic Factors for Overall Survival

Factors included gender, microvascular invasion, ALT/AST, Fib-4, GPR, HALP score and treatment protocol associated with OS after surgical resection in univariate analysis. In multivariate analysis, we found that gender (HR=0.426, 95% CI=0.217–0.833), microvascular invasion (MVI) (HR=0.652, 95% CI=0.447–0.950), ALT/AST (HR=1.845, 95%





Figure 1 Overall survival curves of all patients after surgical resection.



PT: prothrombin time; GPR: γ -glutamyl transpeptidase to platelet ratio; Fib-4: fibrosis-4 score; ALT/AST: alanine aminotransferase/aspartate aminotransferase; HALP: hemoglobin, albumin, lymphocyte, and platelet.

Figure 2 The ROC curves of PT, GPR, Fib-4, ALT/AST and HALP score.

CI=1.093–3.114), HALP score (HR=1.708, 95% CI=1.192–2.448), and treatment protocol (HR=1.882, 95% CI=1.321–2.681) were significant independent risk factors of OS (Table 3, all P < 0.05).

Independent Risk Factors for Overall Survival Rates

The 1-, 3-, and 5-year OS was 98.7%, 76.1%, and 52.5% for male patients; and 100%, 82.9%, and 74.3% for female patients, respectively (Figure 3a). The 1-, 3-, and 5-year OS was 100%, 73.2%, and 43.7% for patients with microvascular invasion positive; and 98.5%, 78.2%, and 59.4% for patients with microvascular invasion negative, respectively (Figure 3b). The 1-, 3-, and 5-year OS was 98.7%, 78.7%, and 57.5% for patients with high ALT/AST; and 100%, 63.6%,

Table 2 Relationship Between HALP Score and Clinical Features in Patients

Features	HALP ^c		
	High (n=134)	Low (n=139)	P value
Gender			P=0.250
Male	120 (89.6%)	118 (84.9%)	
Female	14 (10.4%)	21 (15.1%)	
Age (years)			P=0.130
<60	87 (64.9%)	102 (73.4%)	
≥60	47 (35.1%)	37 (26.6%)	
HBsAg ^a			P=0.548
Positive	103 (76.9%)	111 (79.9%)	
Negative	31 (23.1%)	28 (20.1%)	
Liver cirrhosis			P=0.101
Yes	75 (56.0%)	64 (46.0%)	
No	59 (44.0%)	75 (54.0%)	
Cell differentiation			P=0.770
Poor	57 (42.5%)	65 (46.8%)	
Moderate	68 (50.7%)	66 (47.5%)	
Well	9 (6.7%)	8 (5.8%)	

(Continued)

Table 2 (Continued).

Features	HALP ^e		
	High (n=134)	Low (n=139)	P value
Microvascular invasive			P=0.583
Positive	37 (27.6%)	34 (24.5%)	
Negative	97 (72.4%)	105 (75.5%)	
Tumor number			P=0.076
=1	123 (91.8%)	118 (84.9%)	
≥2	11 (8.2%)	21 (15.1%)	
TNM ^b stage			P=0.001
I-II	115 (85.8%)	97 (69.8%)	
III-IV	19 (14.2%)	42 (30.2%)	
AFP ^c			P=0.092
>7.00 ng/mL	92 (68.7%)	108 (77.7%)	
≤7.00 ng/mL	42 (31.3%)	31 (22.3%)	
PT ^d			P=0.789
≥14.35s	37 (27.6%)	41 (29.5%)	
<14.35s	97 (72.4%)	98 (70.5%)	
Treatment protocol			P=0.727
Surgery only	78 (58.2%)	78 (56.1%)	
Combined treatment	56 (41.8%)	61 (43.9%)	


Notes: ^aHepatitis B surface antigen; ^bTumor node metastasis; ^cAlpha-fetoprotein; ^dProthrombin time; ^eHemoglobin, albumin, lymphocyte, and platelet.

Table 3 Univariate and Multivariate Analysis of Factors for OS

Variable	Univariate Analysis		Multivariate Analysis	
	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Gender (male/female)	0.505 (0.265–0.964)	0.038	0.426 (0.217–0.833)	0.013
Age (<60 years/≥60 years)	0.871 (0.601–1.261)	0.464		
Liver cirrhosis (yes/no)	0.971 (0.684–1.377)	0.868		
TNM ^a stage (I-II/III-IV)	1.383 (0.929–2.057)	0.110		
Cell differentiation (poor/moderate-well)	1.136 (0.798–1.618)	0.480		
Microvascular invasion (positive/negative)	1.530 (1.054–2.222)	0.025	0.652 (0.447–0.950)	0.026
Tumor number (=1/≥2)	1.113 (0.659–1.881)	0.688		
HBsAg ^b (positive/negative)	0.956 (0.625–1.464)	0.837		
AFP ^c (≤7.00 ng/mL/>7.00 ng/mL)	0.953 (0.669–1.358)	0.791		
PT ^d (<14.35s/≥14.35s)	1.324 (0.914–1.918)	0.138		
ALT/AST ^e (<0.568/≥0.568)	1.673 (1.037–2.700)	0.035	1.845 (1.093–3.114)	0.022
Fib-4 ^f (<2.824/≥2.824)	0.635 (0.440–0.916)	0.015	0.737 (0.488–1.112)	0.146
GPR ^g (<0.205/≥0.205)	0.584 (0.394–0.866)	0.007	0.673 (0.443–1.021)	0.063
HALP score ^h (<54.132/≥54.132)	1.527 (1.072–2.176)	0.019	1.708 (1.192–2.448)	0.004
Treatment protocol (surgery only/combined treatment)	1.913 (1.348–2.716)	<0.001	1.882 (1.321–2.681)	<0.001

Notes: ^aTumor node metastasis; ^bHepatitis B surface antigen; ^cAlpha-fetoprotein; ^dProthrombin time; ^eAlanine aminotransferase/aspartate aminotransferase; ^fFibrosis-4 score; ^gγ-glutamyl transpeptidase to platelet ratio; ^hHemoglobin, albumin, lymphocyte, and platelet.

and 39.4% for patients with low ALT/AST, respectively (Figure 3c). The 1-, 3-, and 5-year OS was 99.3%, 84.3%, and 63.4% for patients with high HALP scores; and 98.6%, 69.8%, and 47.5% for patients with low HALP scores, respectively (Figure 3d). The 1-, 3-, and 5-year OS was 99.4%, 84.6%, and 62.8% for patients with surgery only; and 97.4%, 65.8%, and 45.3% for patients with combined treatment, respectively (Figure 3e).




MVI: microvascular invasion; ALT/AST: alanine aminotransferase/aspartate aminotransferase; HALP: hemoglobin, albumin, lymphocyte, and platelet.

Figure 3 Overall survival curves of HCC patients after surgical resection based on gender (a), microvascular invasion (b), ALT/AST (c), HALP score (d) and treatment protocol (e).

Predictive Value of HALP Score in Subgroup

The above analysis shows the HALP score is associated with the TNM stage. So, patients with HCC were divided into different subgroups according to different TNM stages, and the effects of HALP score on OS were studied, respectively. In TNM I–II stage patients, compared with high HALP scores, low HALP scores have worse OS ($P=0.039$, Figure 4a). In TNM III–IV stage patients, there was no significant difference in OS with different HALP scores ($P=0.575$, Figure 4b).

AFP is one of the important markers to monitor the occurrence of HCC and tumor recurrence after hepatectomy. So according to the different levels of AFP, all patients in our study were divided into two subgroups, and the effects of HALP score on OS were studied, respectively. In AFP positive subgroup, compared with high HALP scores, low HALP scores have worse OS ($P=0.042$, Figure 4c). In AFP negative subgroup, there was no significant difference in OS with different HALP scores ($P=0.320$, Figure 4d).



TNM: tumor node metastasis; HALP: hemoglobin, albumin, lymphocyte, and platelet; AFP: alpha-fetoprotein.

Figure 4 Kaplan–Meier curves of OS according to different HALP scores in patients with TNM I–II stage (a), TNM III–IV stage (b), AFP positive (c), and AFP negative (d).

Discussion

HALP score can not only comprehensively evaluate the inflammatory response and nutritional status of the body, but also be obtained in a simple, economical, and non-invasive way, which is an index worthy of clinical use. We have proved that the preoperative HALP score has a statistically significant correlation with the OS of HCC patients undergoing hepatectomy. Moreover, the preoperative HALP score is related to the tumor TNM stage. Subgroup analysis suggests a low HALP score is related to poor OS in TNM I–II stage patients. Because AFP cannot be ignored in HCC, we further analyzed the relationship between HALP scores and OS in different AFP subgroups. Similarly, in AFP positive subgroup, a low HALP score indicates poor OS. In patients with AFP negative and TNM III–IV stage, there is no statistical difference between HALP score and OS, which may be due to insufficient sample size. The results of the subgroup analysis showed that the HALP score was relatively stable as an independent prognostic factor of HCC patients with hepatectomy.

Our results also show gender, MVI status, and ALT/AST are independent influencing factors of OS in HCC patients. This is consistent with previous studies.³⁴ However, in our study, GPR is not an independent factor affecting the postoperative survival of patients with HCC. This is inconsistent with the research conclusions of other scholars.³⁵ It may be associated with the insufficient sample size of our study, the single area of our research object, and the different clinical variables included in different studies. For the controversial Fib-4 in previous studies, this study suggests that the level of Fib-4 has no obvious relationship with the patient's OS. In our study, the prognosis of patients who only receive surgical treatment is better than that of patients who receive comprehensive treatment. This does not mean that comprehensive treatment is an absolute predictive factor of a worse prognosis for patients with HCC. It is mainly because the patient has tumor recurrence during postoperative follow-up that comprehensive anti-tumor treatment will be carried out. This further proves the importance of early identification of patients with high risk and early intervention treatment to improve prognosis.

As we all know, hemoglobin, albumin, lymphocytes, and platelets are all closely associated with the occurrence and development of tumors. Hemoglobin is associated with the progress of tumors.³⁶ Low hemoglobin level is an influential index in the poor overall prognosis of patients with cancer.³⁷ Albumin is produced by the liver, which not only reflects the inflammatory level of the body³⁸ but also reflects the nutritional status of the body.³⁹ At the same time, studies have shown that low albumin level suggests that the overall prognosis of cancer patients is poor.^{40,41} Lymphocytes and platelets belong to immune inflammatory cells. The lymphocyte is one of the important immune cells that kill tumor cells.⁴² Lymphocyte count can reflect the immune ability and inflammatory state to some extent. Many studies have shown inflammatory markers composed of lymphocytes can predict the overall prognosis of tumor patients.^{13,43} Platelets almost participate in the whole process of tumor occurrence and development, including tumor formation, growth, and metastasis.^{44,45} Some scholars believe that platelets have the potential to diagnose tumors,⁴⁶ and monitor the progress of disease.⁴⁷ Many inflammatory markers related to platelets have been proven to be related to the overall prognosis of many cancer patients,^{48–50} including HCC.

As mentioned above, at present, there are many treatments for hepatocellular carcinoma, but they still cannot raise the overall prognosis of HCC patients. Personalized management is a critical factor in improving the overall prognosis of patients with the advent of the era of precise treatment. However, there is no uniform standard for identifying high-risk patients with HCC at present. So, to identify high-risk patients with HCC in the clinic, in addition to pathological features, nutritional status, and inflammatory reactions are also important parts that should not be ignored. Our study's results show that the low HALP score of HCC patients is a symbol of poor prognosis. Therefore, in the early assessment of a patient's risk, it is one of the measures to better judge the prognosis of patients to include the HALP score in the assessment scope.

Our research has some limitations. Firstly, the clinical data were obtained from a single examination before curative resection, which is likely to cause numerical deviation. Secondly, this is a single-center study, and its conclusion is not as convincing as that of a multi-center study. Thirdly, this is a retrospective study, so the research conclusion needs further prospective study verification.

Conclusion

Our research proved the preoperative HALP score is an independent predictive factor of overall prognosis, and a low HALP score indicates a worse prognosis in HCC patients who underwent surgical resection.

Data Sharing Statement

The details of the data are available from the first author upon reasonable request.

Ethics Approval

This is an observational study. This study was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Consent to Participate

Patient consent was waived, as approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Funding

There is no funding to report.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). 中华人民共和国国家卫生健康委员会医政医管局, 原发性肝癌诊疗规范(2019年版). 中华肝脏病杂志. *Liver Cancer*. 2020;9(6):682–720. Chinese. doi:10.1159/000509424
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
3. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. *Lancet*. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
4. Kok B, Abraldes JG. Child-Pugh classification: time to abandon? *Semin Liver Dis*. 2019;39(1):96–103. doi:10.1055/s-0038-1676805
5. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int*. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
6. Yang JD, Larson JJ, Watt KD, et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. *Clin Gastroenterol Hepatol*. 2017;15(5):767–75.e3. doi:10.1016/j.cgh.2016.11.034
7. Salem R, Tselikas L, De Baere T. Interventional treatment of hepatocellular carcinoma. *J Hepatol*. 2022;77(4):1205–1206. doi:10.1016/j.jhep.2022.03.037
8. Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. *Signal Transduct Target Ther*. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
9. Cai R, Song R, Pang P, et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. *BMC Cancer*. 2017;17(1):714. doi:10.1186/s12885-017-3707-5
10. Liu Z, Liu X, Liang J, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects. *Front Immunol*. 2021;12:765101. doi:10.3389/fimmu.2021.765101
11. Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. *Int J Mol Sci*. 2021;22(11):5801. doi:10.3390/ijms22115801
12. Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: the unexplored corner linking tumor microenvironment, biomarkers and interventional radiology. *Cancers*. 2022;15(1). doi:10.3390/cancers15010257
13. Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. *Eur Radiol*. 2020;30(10):5663–5673. doi:10.1007/s00330-020-06931-5
14. George ES, Sood S, Broughton A, et al. The association between diet and hepatocellular carcinoma: a systematic review. *Nutrients*. 2021;13(1):172. doi:10.3390/nu13010172
15. Jiang Y, Tu X, Zhang X, et al. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. *Support Care Cancer*. 2020;28(11):5569–5579. doi:10.1007/s00520-020-05478-x
16. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J Clin*. 2012;62(4):243–274. doi:10.3322/caac.21142
17. Xu H, Zheng X, Ai J, Yang L. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. *Int Immunopharmacol*. 2023;114:109496. doi:10.1016/j.intimp.2022.109496

18. Xu SS, Li S, Xu HX, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. *World J Gastroenterol.* 2020;26(8):828–838. doi:10.3748/wjg.v26.i8.828
19. Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: a propensity matched retrospective cohort study. *World J Gastroenterol.* 2022;28(27):3476–3487. doi:10.3748/wjg.v28.i27.3476
20. Hu SJ, Zhao XK, Song X, et al. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma. *World J Gastroenterol.* 2021;27(4):321–335. doi:10.3748/wjg.v27.i4.321
21. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. *Gut.* 2016;65(8):1369–1376. doi:10.1136/gutjnl-2015-309260
22. Zhang W, Sun M, Chen G, et al. Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection. *Gut.* 2018;67(5):989–991. doi:10.1136/gutjnl-2017-313896
23. Park YE, Kim BK, Park JY, et al. Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. *J Gastroenterol Hepatol.* 2017;32(6):1221–1229. doi:10.1111/jgh.13653
24. Liang LY, Lee HW, Wong VW, et al. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. *Clin Mol Hepatol.* 2021;27(3):499–509. doi:10.3350/cmh.2020.0333
25. Tamaki N, Kurosaki M, Yasui Y, et al. Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. *Clin Infect Dis.* 2021;73(9):e3349–e3354. doi:10.1093/cid/ciaa1307
26. Cholankeril G, Kramer JR, Chu J, et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. *J Hepatol.* 2022;78(3):493–500. doi:10.1016/j.jhep.2022.10.035
27. Ke MY, Zhang M, Su Q, et al. Gamma-glutamyl transpeptidase to platelet ratio predicts short-term outcomes in hepatocellular carcinoma patients undergoing minor liver resection. *J Surg Res.* 2018;231:403–410. doi:10.1016/j.jss.2018.05.049
28. Zhang J, Wang T, Xu L, Wang P, Zhang M, Xu M. Development and validation of a prognostic model based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma patients. *Clin Chim Acta.* 2020;511:107–116. doi:10.1016/j.cca.2020.09.038
29. Feng JW, Qu Z, Wu BQ, Sun DL, Jiang Y. The preoperative fibrosis score 4 predicts posthepatectomy liver failure in patients with hepatocellular carcinoma. *Ann Hepatol.* 2019;18(5):701–707. doi:10.1016/j.aohep.2019.04.017
30. Lin PT, Teng W, Jeng WJ, et al. The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. *J Formos Med Assoc.* 2020;119(2):635–643. doi:10.1016/j.jfma.2019.08.019
31. Zhou P, Chen B, Miao XY, et al. Comparison of FIB-4 index and Child-Pugh score in predicting the outcome of hepatic resection for hepatocellular carcinoma. *J Gastrointest Surg.* 2020;24(4):823–831. doi:10.1007/s11605-019-04123-1
32. Yoshimasu Y, Furuichi Y, Kasai Y, et al. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C. *J Gastrointest Liver Dis.* 2019;28(1):63–71. doi:10.15403/jgld.2014.1121.281.hpc
33. Choi WM, Lee JH, Ahn H, et al. Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. *Liver Int.* 2015;35(8):1992–2000. doi:10.1111/liv.12776
34. Peng Z, Chen S, Xiao H, et al. Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediate-stage hepatocellular carcinoma. *Radiology.* 2019;292(1):237–247. doi:10.1148/radiol.2019181818
35. Wu W, Wang Q, Han D, et al. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. *Cancer Cell Int.* 2021;21(1):500. doi:10.1186/s12935-021-02204-3
36. Belcher DA, Ju JA, Baek JH, et al. The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: a theoretical and experimental study. *PLoS One.* 2018;13(2):e0191275. doi:10.1371/journal.pone.0191275
37. Xia L, Hu G, Guzzo TJ. Prognostic significance of preoperative anemia in patients undergoing surgery for renal cell carcinoma: a meta-analysis. *Anticancer Res.* 2017;37(6):3175–3181. doi:10.21873/anticancer.11677
38. Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marín-Ciancas F, Malafarina V. Serum albumin and health in older people: review and meta analysis. *Maturitas.* 2015;81(1):17–27. doi:10.1016/j.maturitas.2015.02.009
39. Eckart A, Struja T, Kutz A, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. *Am J Med.* 2020;133(6):713–22.e7. doi:10.1016/j.amjmed.2019.10.031
40. Ataseven B, du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. *Gynecol Oncol.* 2015;138(3):560–565. doi:10.1016/j.ygyno.2015.07.005
41. Lei J, Wang Y, Guo X, et al. Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients. *Future Oncol.* 2020;16(8):307–316. doi:10.2217/fon-2019-0732
42. Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? *Clin Cancer Res.* 2015;21(22):5047–5056. doi:10.1158/1078-0432.CCR-15-0685
43. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med.* 2020;18(1):360. doi:10.1186/s12916-020-01817-1
44. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. *Cancer Cell.* 2018;33(6):965–983. doi:10.1016/j.ccell.2018.03.002
45. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. *J Hematol Oncol.* 2018;11(1):125. doi:10.1186/s13045-018-0669-2
46. Roweth HG, Battinelli EM. Lessons to learn from tumor-educated platelets. *Blood.* 2021;137(23):3174–3180. doi:10.1182/blood.2019003976
47. Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. *Cancer Res.* 2018;78(13):3407–3412. doi:10.1158/0008-5472.CAN-18-0887
48. Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. *World J Gastroenterol.* 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
49. Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. *Clin Chim Acta.* 2018;483:48–56. doi:10.1016/j.cca.2018.04.023
50. Li SP, Cao D, He JH, Lou MG, Tu XX, Li Y. High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis. *Expert Rev Gastroenterol Hepatol.* 2022;16(2):193–199. doi:10.1080/17474124.2022.2031977

Journal of Hepatocellular Carcinoma

Dovepress

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal>